1. Home
  2. BMRA vs CTXR Comparison

BMRA vs CTXR Comparison

Compare BMRA & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Biomerica Inc.

BMRA

Biomerica Inc.

N/A

Current Price

$1.78

Market Cap

11.5M

Sector

Health Care

ML Signal

N/A

Logo Citius Pharmaceuticals Inc.

CTXR

Citius Pharmaceuticals Inc.

SELL

Current Price

$0.46

Market Cap

13.4M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
BMRA
CTXR
Founded
1971
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.5M
13.4M
IPO Year
1995
2010

Fundamental Metrics

Financial Performance
Metric
BMRA
CTXR
Price
$1.78
$0.46
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
21.9K
★ 178.9K
Earning Date
10-15-2026
08-14-2026
Dividend Yield
N/A
N/A
EPS Growth
39.81
★ 43.38
EPS
★ N/A
N/A
Revenue
★ $4,453,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$104.18
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$1.45
$0.45
52 Week High
$3.21
$2.19

Technical Indicators

Market Signals
Indicator
BMRA
CTXR
Relative Strength Index (RSI) 39.82 33.59
Support Level $1.50 N/A
Resistance Level $2.23 $0.61
Average True Range (ATR) 0.09 0.03
MACD -0.06 -0.01
Stochastic Oscillator 18.26 10.08

Price Performance

Historical Comparison
BMRA
CTXR

About BMRA Biomerica Inc.

Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America generating key revenue from North American Markets.

About CTXR Citius Pharmaceuticals Inc.

Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.

Share on Social Networks: